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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER561Exercise Training for Heart FailureJill Downing, Gary J. Balady
Downing and Balady review the pathophysiologic features that underlie exercise intolerance in
patients with heart failure. Randomized controlled trials have found that exercise improves
endothelial function, inflammatory markers, sympathetic neural activation, and skeletal muscle
metabolism in patients with heart failure. Further research is needed to determine the most
efficacious form of exercise, such as the role of variable intensity and resistance training
compared with a standard aerobic prescription. Currently, exercise training is underutilized,
and the various impediments to wider adoption are addressed, including provider acceptance,
insurance coverage, and patient adherence.CLINICAL RESEARCH VALVULAR HEART DISEASE570ACEI/ARB Therapy May Improve Outcomes in Patients With ASM. Adnan Nadir, Li Wei, Douglas H. J. Elder, Renata Libianto, Tiong K. Lim, Maheshwar Pauriah,
Stuart D. Pringle, Alex D. Doney, Anna-Maria Choy, Allan D. Struthers, Chim C. Lang
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)
are perceived to be relatively contraindicated in aortic stenosis (AS) because of vasodilation;
however, inhibitors of the renin-angiotensin system (RAS) may have beneficial effects on left
ventricular remodeling. Nadir and colleagues combined data from a large echocardiographic
database and an electronic medical records system to determine the impact of RAS inhibitors
in patients with AS. One-third of patients with moderate or severe AS were taking either an
ACEI or an ARB, and these patients had significantly lower all-cause mortality and fewer
cardiovascular events. This large observational study did not find adverse effects from ACEI/
ARB therapy and suggests that it may be beneficial in patients with AS.
Editorial Comment: Gerard P. Aurigemma, John F. Keaney, Jr, p. 577(continued on page A-24)
AUGUST 2, 2011 (continued) A-24VALVULAR HEART DISEASE581It Is Safe Not to Repair Post-Stenotic Ascending Aorta Dilation at Time of AVRMario Gaudino, Amedeo Anselmi, Mauro Morelli, Claudio Pragliola, Vasileios Tsiopoulos,
Franco Glieca, Gianfederico Possati
The ascending aorta may dilate in patients with aortic stenosis caused by the high velocity
blood flow. Gaudino and colleagues reviewed the outcomes of patients with moderate post-
stenotic ascending aorta dilation (50 to 59 mm) who underwent aortic valve replacement
(AVR) surgery. Patients were excluded if they had a bicuspid aortic valve or connective tissue
disorder. Median follow-up for the 93 subjects was 14.7 years. No patients experienced acute
aortic events (rupture, dissection, pseudoaneurysm), and no patient required aortic repair.
Mean aortic diameter was 56 mm pre-operatively and 57 mm at the end of the follow-up. In
the absence of connective tissue disorders, AVR alone is sufficient to prevent further aortic
expansion in patients with moderate post-stenotic dilation of the ascending aorta.Editorial Comment: Donald D. Glower, p.585HEART RHYTHM DISORDERS587Long-Term Follow-Up of Patients With Short QT SyndromeCarla Giustetto, Rainer Schimpf, Andrea Mazzanti, Chiara Scrocco, Philippe Maury, Olli Anttonen,
Vincent Probst, Jean-Jacques Blanc, Pascal Sbragia, Paola Dalmasso, Martin Borggrefe, Fiorenzo Gaita
Giustetto and colleagues report on the clinical characteristics and long-term outcomes of
53 patients with short QT syndrome (SQTS). Sudden death was the clinical presentation in
32%. The average QT interval was 282 ms, and the corrected QT interval (QTc) was
314 ms. A mutation in genes related to SQTS was found in 23% of the probands; most
of them had a gain of function mutation in HERG. Patients with a HERG mutation
had a shorter QTc at baseline and a greater QTc prolongation with hydroquinidine
(HQ) treatment. The incidence of arrhythmic events during follow-up was 4.9% per year
not treated with HQ, while no events occurred in those receiving HQ. These findings
help to define the presentation and clinical outcomes of patients with SQTS and strongly
suggest that HQ has therapeutic benefits.HEART RHYTHM DISORDERS596AF Ablation May Be Safe and Effective in Patients With MVRAyman A. Hussein, Oussama M. Wazni, Serge Harb, Lee Joseph, Mohammed Chamsi-Pasha,
Mandeep Bhargava, David O. Martin, Thomas Dresing, Thomas Callahan, Mohamed Kanj,
Andrea Natale, Bruce D. Lindsay, Walid I. Saliba
Patients with a mechanical mitral valve replacement (MVR) are at increased risk for atrial
fibrillation (AF), but complications have been reported in patients with a mechanical MVR
during AF ablation, including prosthesis disk embolization, transient ischemic attacks, and
catheter entrapment within the prosthetic valve. Hussein and colleagues reviewed their results
with 81 patients with MVR who underwent AF ablation. No entrapment of catheters or
stroke occurred, and there was no difference in rates of procedure-related complications
compared with a control group. Patients with a previous MVR were more likely to have AF
recurrence (49% vs. 28% after a single ablation). At last follow-up, 83% of MVR patients had
their arrhythmia controlled (69% not taking antiarrhythmic drugs).
(continued on page A-25)







ECARDIAC IMAGING603PET Imaging of Glucose Uptake May Measure Hypoxia Rather Than InflammationEduardo J. Folco, Yuri Sheikine, Viviane Z. Rocha, Thomas Christen, Eugenia Shvartz,
Galina K. Sukhova, Marcelo F. Di Carli, Peter Libby
Positron emission tomography (PET) using 18fluorine-labeled 2-deoxy-D-glucose (FdG) is
eing used to image active atherosclerotic plaques. Folco and colleagues investigated the
timuli for glucose uptake in cells exposed to conditions simulating those in atheromas.
ypoxia, but not pro-inflammatory cytokines, stimulated glucose uptake in macrophages and
oam cells. Immunohistochemical study of human plaques revealed increased expression of
roteins regulating glucose utilization in macrophage-rich regions of the plaques—regions
reviously associated with hypoxia. These results suggest that FdG uptake in atheromatous
laques reflects hypoxia-stimulated macrophages rather than mere inflammation.ditorial Comment: Joseph C. Wu, Patricia K. Nguyen, p. 615BIOMARKERS618BNP Levels May Be Decreased by TestosteroneCarolyn S. P. Lam, Susan Cheng, Karen Choong, Martin G. Larson, Joanne M. Murabito,
Christopher Newton-Cheh, Shalender Bhasin, Elizabeth L. McCabe, Karen K. Miller,
Margaret M. Redfield, Ramachandran S. Vasan, Andrea D. Coviello, Thomas J. Wang
Lam and colleagues investigated why women tend to have higher circulating natriuretic
peptide concentrations than men. Plasma N-terminal pro–B-type natriuretic peptide
(NT-proBNP), total testosterone, and sex hormone-binding globulin (SHBG) were measured
in over 4,000 men and women. NT-proBNP levels were altered by sex/hormone status, with
the lowest levels in men and the highest levels in pre-menopausal women taking hormonal
contraceptives. These relationships remained significant after adjusting for age, body mass
index, and cardiovascular risk factors, but not after adjusting for free testosterone levels. These
findings suggest that lower circulating androgens and the potentiating effect of exogenous
female hormone therapy contribute to the higher circulating NT-proBNP concentrations in
women.
Editorial Comment: Aldo Clerico, Claudio Passino, Michele Emdin, p. 627(continued on page A-26)
AUGUST 2, 2011 (continued) A-26CARDIOVASCULAR GENETICS/GENOMICS629Genetic Variant in ANP Gene Associated With Favorable Metabolic ProfileValentina Cannone, Guido Boerrigter, Alessandro Cataliotti, Lisa C. Costello-Boerrigter, Timothy M. Olson,
Paul M. McKie, Denise M. Heublein, Brian D. Lahr, Kent R. Bailey, Maurizio Averna,
Margaret M. Redfield, Richard J. Rodeheffer, John C. Burnett Jr
Several lines of evidence suggest that natriuretic peptides may have favorable metabolic effects;
rs5068 is a genetic variant in the 3= untranslated region of the atrial natriuretic peptide (ANP)
gene associated with higher levels of circulating N-terminal (NT)-proANP and NT-pro–B-
type natriuretic peptide. Cannone and colleagues genotyped 1,608 randomly selected subjects.
Carriers of the G allele had higher plasma levels of NT-proANP, lower levels of C-reactive
protein, lower body mass index, smaller waist circumference, and lower systolic blood
pressure, resulting in lower prevalence of the metabolic syndrome. These findings confirm the
association of ANP and beneficial effects on several markers of cardiometablic risk.HEALTH SERVICES RESEARCH637Cardiac Quality Core Measures and MortalityTracy Y. Wang, David Dai, Adrian F. Hernandez, Deepak L. Bhatt, Paul A. Heidenreich,
Gregg C. Fonarow, Eric D. Peterson
Wang and colleagues investigated the degree to which hospital performance for acute
myocardial infarction (AMI) and heart failure (HF) core measures are correlated with each
other and with mortality. Median hospital adherence to AMI and HF composite measures
were 93% and 92%, respectively, with only a modest correlation between these 2 composite
metrics. Hospitals with superior performance on both processes had significantly lower
adjusted in-hospital mortality. These results suggest that a comprehensive cardiac score for
both AMI and HF may facilitate care quality improvement and patient outcomes.CONGENITAL HEART DISEASE645Warfarin and Aspirin Equally Effective After Fontan SurgeryPaul Monagle, Andrew Cochrane, Robin Roberts, Cedric Manlhiot, Robert Weintraub, Barbara Szechtman,
Marina Hughes, Maureen Andrew, Brian W. McCrindle, for the Fontan Anticoagulation Study Group
Intravascular thrombosis and embolic phenomena can frequently occur after Fontan surgery.
Monagle and colleagues performed a multicenter randomized trial of acetylsalicylic acid
(ASA) versus warfarin after a Fontan procedure. During 2 years of follow-up with mandated
transesophageal echocardiogram at 3 months and 2 years, there were 13 thrombotic events in
the heparin/warfarin group (3 clinical, 10 routine echocardiography) and 12 in the ASA
group (4 clinical, 8 routine echocardiography). Major bleeding occurred in 1 patient in each
group. ASA and warfarin have similar outcomes, but neither regimen satisfactorily prevents
thrombotic events.Editorial Comment: Charles E. Canter, p. 652
